Vanguard Asset Management
RVMD icon

Vanguard Asset Management’s Revolution Medicines RVMD Stock Holding History

Vanguard Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Buy
92,056
+11,542
+14% +$1.69M 0.01% 583
2026
Q1 		$7.83M Buy
+80,514
New +$8.13M 0.01% 731

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Asset Management's RVMD Position: Q2 2026 in Review

Vanguard Asset Management increased its Revolution Medicines (RVMD) stake by 14% in Q2 2026, buying an estimated $1.69M and bringing the position to 92,056 shares worth $17.2M. The position accounts for 0.01% of the portfolio, ranked #583.

Vanguard Asset Management first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 637 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Vanguard Asset Management held 92,056 shares of Revolution Medicines worth $17.2M as of Q2 2026.
  • Vanguard Asset Management bought 11,542 Revolution Medicines shares in Q2 2026, an estimated $1.69M.
  • Revolution Medicines made up 0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #583 holding.
  • Vanguard Asset Management first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 637 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.